Summary & Overview
HCPCS J9259: Paclitaxel Protein-Bound Particles Injection, 1 mg
HCPCS Level II code J9259 identifies an injection of paclitaxel protein-bound particles (American Regent), billed per 1 mg, and explicitly noted as not therapeutically equivalent to J9264. This code matters nationally because it distinguishes a specific nanoparticle albumin-bound paclitaxel formulation from other paclitaxel products, affecting billing, supply management, and formulary placement across outpatient infusion settings. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise understanding of the code’s clinical and billing identity, where the service is typically delivered, and what to expect in payer coverage patterns and reimbursement categorization. The publication outlines benchmarks for utilization and unit-based billing, highlights policy considerations tied to non-equivalence with related paclitaxel codes, and summarizes the clinical context for use in oncology infusion. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9259 represents an injection of paclitaxel protein-bound particles (American Regent), billed per 1 mg unit. The description specifies that this formulation is not therapeutically equivalent to J9264, indicating a distinct product and billing pathway.
Service type: Drug administration (intravenous chemotherapy)
Typical site of service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a solid tumor (commonly metastatic breast, non-small cell lung, or pancreatic cancer) scheduled to receive chemotherapy with nanoparticle albumin-bound paclitaxel (Abraxane equivalent: paclitaxel protein-bound particles). The medication is administered intravenously in an outpatient oncology infusion center or hospital outpatient department. Prior to infusion the patient undergoes chemotherapy consent, baseline vital signs, review of recent laboratory studies (complete blood count, liver function tests), and an assessment for peripheral neuropathy, hypersensitivity history, and concomitant medications. The infusion is prepared by pharmacy per weight-based dosing; a nurse performs line verification and administers the drug via infusion pump over the recommended infusion time. Typical sites of service: outpatient infusion center, hospital outpatient department, or ambulatory surgical center for patients receiving supportive procedures. Common clinical workflow steps: physician orders the oncology regimen with J9259 per milligram, pharmacy compounds and labels the dose, nursing performs pre-medication assessment and administers infusion, post-infusion monitoring for adverse reactions, and documentation of dose, lot number, and infusion parameters in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |